Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature

European Journal of Heart Failure

Volumn 18, Issue 12, 2016, Pages 1430-1441

  Verdonschot, Job ^a   Hazebroek, Mark ^a   Merken, Jort ^a   Debing, Yannick ^a   Dennert, Robert ^a   Brunner La Rocca, Hans Peter ^a   Heymans, Stephane ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dilated cardiomyopathy; Endomyocardial biopsy; Myocarditis; Parvovirus B19; Prognosis; Viral load

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN; MESSENGER RNA; NONSTRUCTURAL PROTEIN 1; PLACEBO; PROTEIN VP1; PROTEIN VP2;

CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENTEROVIRUS INFECTION; ERYTHEMA INFECTIOSUM; GENETIC BACKGROUND; GENETIC SUSCEPTIBILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN PARVOVIRUS B19; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIXED INFECTION; MOLECULAR MIMICRY; NONHUMAN; PARVOVIRUS INFECTION; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRAL CLEARANCE; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS REPLICATION; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHY, DILATED; HEART; MYOCARDITIS; PARVOVIRIDAE INFECTIONS; PATHOLOGY; VIROLOGY;

BIOPSY; CARDIOMYOPATHY, DILATED; HEART; HUMANS; MYOCARDITIS; MYOCARDIUM; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREVALENCE;

EID: 84991503794     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.665     Document Type: Review

References (98)

1. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526–38.
2. Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965–1970.
3. D'Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001;85:499–504.
4. Pankuweit S, Portig I, Eckhardt H, Crombach M, Hufnagel G, Maisch B. Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease. Herz 2000;25:221–226.
5. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction. Circulation 2005;111:887–893.
6. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008;29:2073–2082.
7. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997;78:539–543.
8. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM, Chinnock RE, Towbin JA. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997;96:3549–3554.
9. Stewart GC, Lopez-Molina J, Gottumukkala RV, Rosner GF, Anello MS, Hecht JL, Winters GL, Padera RF, Baughman KL, Lipes MA. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 2011;4:71–78.
10. Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 2003;34:92–95.
11. Murry CE, Jerome KR, Reichenbach DD. Fatal parvovirus myocarditis in a 5-year-old girl. Hum Pathol 2001;32:342–345.
12. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009;47:106–110.
13. Lotze U, Egerer R, Gluck B, Zell R, Sigusch H, Erhardt C, Heim A, Kandolf R, Bock T, Wutzler P, Figulla HR. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol 2010;82:1449–1457.
14. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–597.
15. Gallinella G. arvovirus B19 achievements and challenges. ISRN Virol 2013; doi: 10.5402/2013/898730.
16. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010;362:1248–9.
17. Zakrzewska K, Cortivo R, Tonello C, Panfilo S, Abatangelo G, Giuggioli D, Ferri C, Corcioli F, Azzi A. Human parvovirus B19 experimental infection in human fibroblasts and endothelial cell cultures. Virus Res 2005;114:1–5.
18. Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology 2011;411:50–64.
19. Guan W, Wong S, Zhi N, Qiu J. The genome of human parvovirus B19 virus can replicate in non-permissive cells with the help of adenovirus genes and produces infectious virus. J Virol 2009;83:9541–9553.
20. Bock CT, Duchting A, Utta F, Brunner E, Sy BT, Klingel K, Lang F, Gawaz M, Felix SB, Kandolf R. Molecular phenotypes of human parvovirus B19 patients with myocarditis. World J Cardiol 2014;6:183–195.
21. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 2004;193:101–107.
22. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993;262:114–117.
23. Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003;102:3927–3933.
24. Munakata Y, Saito-Ito T, Kumara-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005;106:3449–3456.
25. Duechting A, Tschope C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R, Bock CT. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol 2008;82:7942–7952.
26. Bock CT, Klingel K, Aberle S, Duechting A, Lupescu A, Lang F, Kandolf R. Human parvovirus B19: a new emerging pathogen of inflammatory cardiomyopathy. J Vet Med B 2005;52:340–343.
27. + exchanger activity by parvovirus B19 protein NS1. Cellular physiology and biochemistry. Int J Exp Cell Physiol Biochem Pharmacol 2009;23:211–220.
28. Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, Modrow S. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002;76:2014–2018.
29. 2+ entry by human parvovirus B19 capsid protein VP1. J Virol 2006;80:11370–11380.
30. Tavora F, Gonzalez-Cuyar LF, Dalal JS, O'Malley MT, Zhao R, Peng HQ, Burke AP. Fatal parvoviral myocarditis: a case report and review of literature. Diagn Pathol 2008;3:21.
31. Norbeck O, Isa A, Pohlmann C, Broliden K, Kasprowicz V, Bowness P, Klenerman P, Tolfvenstam T. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005;79:12117–12121.
32. Streitz M, Noutsias M, Volkmer R, Rohde M, Brestrich G, Block A, Klippert K, Kotsch K, Ay B, Hummel M, Kuhl U, Lassner D, Schultheiss HP, Volk HD, Kern F. NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy. PloS One 2008;3:e2361.
33. Bultmann BD, Sotlar K, Klingel K. Parvovirus B19. N Engl J Med 2004;350:2006–2007; author reply 2006–2007.
34. Kuhl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, Krautwurm L, Poller W, Schultheiss HP, Kandolf R. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 2003;108:945–950.
35. Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, Modrow S. Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clinical Virol 2009;44:27–32.
36. Klein RM, Jiang H, Niederacher D, Adams O, Du M, Horlitz M, Schley P, Marx R, Lankisch MR, Brehm MU, Strauer BE, Gabbert HE, Scheffold T, Gulker H. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Zeitschr Kardiol 2004;93:300–309.
37. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003;34:497–503.
38. Kuethe F, Lindner J, Matschke K, Wenzel JJ, Norja P, Ploetze K, Schaal S, Kamvissi V, Bornstein SR, Schwanebeck U, Modrow S. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009;49:1660–1666.
39. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Fritz P, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109:1250–1258.
40. Greulich S, Kindermann I, Schumm J, Perne A, Birkmeier S, Grun S, Ong P, Schaufele T, Klingel K, Schneider S, Kandolf R, Bohm M, Sechtem U, Mahrholdt H. Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy. Clin Res Cardiol 2016;105:37–52.
41. Mavrogeni S, Spargias C, Bratis C, Kolovou G, Markussis V, Papadopoulou E, Constadoulakis P, Papadimitropoulos M, Douskou M, Pavlides G, Cokkinos D. Myocarditis as a precipitating factor for heart failure: evaluation and 1-year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy. Eur J Heart Fail 2011;13:830–837.
42. Kuhl U, Lassner D, Dorner A, Rohde M, Escher F, Seeberg B, Hertel E, Tschope C, Skurk C, Gross UM, Schultheiss HP, Poller W. A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Res Cardiol 2013;108:372.
43. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581–1590.
44. Vallbracht KB, Schwimmbeck PL, Kuhl U, Rauch U, Seeberg B, Schultheiss HP. Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates. Circulation 2005;111:1784–1791.
45. Kerr JR. The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol 2016;69:279–291.
46. Page C, Francois C, Goeb V, Duverlie G. Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses. J Clin Virol 2015;72:69–74.
47. Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, Severi AB, Puccetti A. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998;28:936–948.
48. Poole BD, Kivovich V, Gilbert L, Naides SJ. Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis. Int J Med 2011;8:88–96.
49. Thammasri K, Rauhamaki S, Wang L, Filippou A, Kivovich V, Marjomaki V, Naides SJ, Gilbert L. Human parvovirus B19 induced apoptotic bodies contain altered self-antigens that are phagocytosed by antigen presenting cells. PloS One 2013;8:e67179.
50. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–2648, 2648a–2648d.
51. Lotze U, Egerer R, Tresselt C, Gluck B, Dannberg G, Stelzner A, Figulla HR. Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med Microbiol Immunol 2004;193:75–82.
52. Donoso Mantke O, Meyer R, Prosch S, Nitsche A, Leitmeyer K, Kallies R, Niedrig M. High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients' pool. J Heart Lung Transplant 2005;24:1632–1638.
53. Koepsell SA, Anderson DR, Radio SJ. Parvovirus B19 is a bystander in adult myocarditis. Cardiovasc Pathol 2012;21:476–481.
54. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326–1333.
55. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005;111:879–886.
56. Moimas S, Zacchigna S, Merlo M, Buiatti A, Anzini M, Dreas L, Salvi A, Di Lenarda A, Giacca M, Sinagra G. Idiopathic dilated cardiomyopathy and persistent viral infection: lack of association in a controlled study using a quantitative assay. Heart Lung Circ 2012;21:787–93.
57. Nielsen TS, Hansen J, Nielsen LP, Baandrup UT, Banner J. The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts. Forensic Sci Med Pathol 2014;10:344–350.
58. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, Hare J, Bricker JT, Bowles KR, Towbin JA. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466–472.
59. Wang X, Zhang G, Liu F, Han M, Xu D, Zang Y. Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization. J Clin Virol 2004;31:20–24.
60. Kubanek M, Sramko M, Berenova D, Hulinska D, Hrbackova H, Maluskova J, Lodererova A, Malek I, Kautzner J. Detection of Borrelia burgdorferi sensu lato in endomyocardial biopsy specimens in individuals with recent-onset dilated cardiomyopathy. Eur J Heart Fail 2012;14:588–596.
61. Noutsias M, Rohde M, Goldner K, Block A, Blunert K, Hemaidan L, Hummel M, Blohm JH, Lassner D, Kuhl U, Schultheiss HP, Volk HD, Kotsch K. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail 2011;13:611–618.
62. Donoso Mantke O, Nitsche A, Meyer R, Klingel K, Niedrig M. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 2004;31:32–39.
63. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 2010;15:193–201.
64. Dennert R, van Paassen P, Wolffs P, Bruggeman C, Velthuis S, Felix S, van Suylen RJ, Crijns HJ, Cohen Tervaert JW, Heymans S. Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases. Clin Vaccine Immunol 2012;19:1182–1187.
65. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005;193:363–365.
66. Corcioli F, Zakrzewska K, Rinieri A, Fanci R, Innocenti M, Civinini R, De Giorgi V, Di Lollo S, Azzi A. Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. J Med Virol 2008;80:2005–2011.
67. Corsten MF, Heggermont W, Papageorgiou A, Deckx S, Tijsma A, Verhesen W, van Leeuwen R, Carai P, Thibaut HJ, Custers K, Summer G, Hazebroek MR, Verheyen F, Neyts J, Schroen B, Heymans S. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. Eur Heart J 2015;36:2909–2919.
68. Besler C, Urban D, Watzka S, Lang D, Rommel KP, Kandolf R, Klingel K, Thiele H, Linke A, Schuler G, Adams V, Lurz P. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail 2016;18:1442–1451.
69. Kuhl U, Rohde M, Lassner D, Gross UM, Escher F, Schultheiss HP. miRNA as activity markers in Parvo B19 associated heart disease. Herz 2012;37:637–643.
70. Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek MR, van Leeuwen R, Gijbels MJ, Wijnands E, Biessen EA, De Winther MP, Stassen FR, Carmeliet P, Kauppinen S, Schroen B, Heymans S. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res 2012;111:415–425.
71. Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, Verdonschot J, Merken JJ, de Vries B, Wolffs PF, Crijns HJ, Brunner-La Rocca HP, Heymans S. Prognostic relevance of gene–environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol 2015;66:1313–1323.
72. Ruppert V, Maisch B. Molecular signatures and the study of gene expression profiles in inflammatory heart diseases. Herz 2012;37:619–626.
73. Dou Q, Peng Y, Zhou B, Lin J, Li Y, Yang H, Xie Q, Li C, Zhang L, Rao L. Association of innate immune IFIH1 gene polymorphisms with dilated cardiomyopathy in a Chinese population. Immunol Invest 2014;43:627–37.
74. Wittchen F, Suckau L, Witt H, Skurk C, Lassner D, Fechner H, Sipo I, Ungethum U, Ruiz P, Pauschinger M, Tschope C, Rauch U, Kuhl U, Schultheiss HP, Poller W. Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets. J Mol Med (Berl) 2007;85:257–271.
75. Linhartova K, Hubacek P, Zemanek D, Kodetova D, Zajac M, Setina M, Veselka J. Presence of the viral genome in the myocardial tissue of patients without clinical suspicion of myocarditis. Cardiovasc Pathol 2013;22:113–114.
76. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clinic Proc 1989;64:1235–1245.
77. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M, Sechtem U. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900–909.
78. Baccouche H, Mahrholdt H, Meinhardt G, Mehrer R, Voehringer M, Hill S, Klingel K, Kandolf R, Sechtem U, Yilmaz A. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J 2009;30:2869–2879.
79. Ohlow MA, Chen TH, Schmidt A, Saenger J, Lauer B. Clinical profile of patients with advanced age and inflammatoric dilated cardiomyopathy on endomyocardial biopsy. J Geriatr Cardiol 2015;12:605–612.
80. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076–1082.
81. Kuethe F, Sigusch HH, Hilbig K, Tresselt C, Gluck B, Egerer R, Figulla HR. Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy. Am Heart J 2007;153:850–858.
82. Escher F, Modrow S, Sabi T, Kuhl U, Lassner D, Schultheiss HP, Noutsias M. Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008;14:CR589–CR597.
83. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002;76:9124–9134.
84. Kuhl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008;80:1243–1251.
85. Ruppert V, Meyer T, Balbach A, Richter A, Muller HH, Maisch B, Pankuweit S, German Heart Failure Network. Genotype-specific effects on left ventricular function in parvovirus B19-positive patients with dilated cardiomyopathy. J Med Virol 2011;83:1818–1825.
86. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639–648.
87. Nowalany-Kozielska E, Koziel M, Domal-Kwiatkowska D, Wojciechowska C, Jachec W, Kawecki D, Tomasik A, Przywara-Chowaniec B, Weglarz L, Reichman-Warmusz E, Wojnicz R. Clinical significance of viral genome persistence in the myocardium of patients with dilated cardiomyopathy. Intervirology 2016;58:350–356.
88. Zimmermann O, Bienek-Ziolkowski M, Wolf B, Vetter M, Baur R, Mailander V, Hombach V, Torzewski J. Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res Cardiol 2009;104:591–599.
89. Vigneswaran TV, Brown JR, Breuer J, Burch M. Parvovirus B19 myocarditis in children: an observational study. Arch Dis Child 2016;101:177–180.
90. Molina KM, Garcia X, Denfield SW, Fan Y, Morrow WR, Towbin JA, Frazier EA, Nelson DP. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol 2013;34:390–397.
91. Miranda JO, Costa L, Rodrigues E, Teles EL, Baptista MJ, Areias JC. Paediatric dilated cardiomyopathy: clinical profile and outcome. The experience of a tertiary centre for paediatric cardiology. Cardiol Young 2015;25:333–337.
92. Gagliardi MG, Fierabracci A, Pilati M, Chinali M, Bassano C, Saura F, Giovannoni I, Francalanci P. The impact of specific viruses on clinical outcome in children presenting with acute heart failure. Int J Mol Sci 2016;17:486.
93. Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol 2015;115:499–504.
94. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
95. Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M. Long-term ourcome and its predictors in giant cell myocarditis. Eur J Heart Fail 2016;18:1452–1458.
96. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis – diagnosis, treatment options, and current controversies. Nat Rev Cardiol 2015;12:670–680.
97. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, Siedentop H, Kuhl U. Betaferon in chronic viral myocarditis (BICC) trial: effects of interferon-beta treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016;105:763–773.
98. Schmidt-Lucke C, Spillmann F, Bock T, Kuhl U, Van Linthout S, Schultheiss HP, Tschope C. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus B19 infection. J Infect Dis 2010;201:936–945.